Liu S.,Navy General Hospital PLA |
Yin F.,Navy General Hospital PLA |
Zhang J.,Navy General Hospital PLA |
Wicha M.S.,University of Michigan |
And 5 more authors.
Journal of Cellular Biochemistry | Year: 2014
To investigate the expressional alternation of microRNAs (miRNA) during the malignant transformation and development of human glioma, we measured miRNA expression profile as well as mRNA expression profile in normal human neural stem cells (hNSCs) and human glioma stem cells (hGSCs). We found 116 miRNA up-regulated and 62 miRNA down-regulated in GSCs. On the other hand, we identified 1,372 mRNA down-regulated, and 1,501 mRNA up-regulated in GSCs compared to those in NSCs. We then analyzed the pathways and the predicted target genes of the miRNAs which differ significantly in expression between GSCs and NSCs using the statistical enrichment methods. These target mRNAs are involved in many cancer-related signaling pathways, such as cell cycle, axon guidance, glioma development, adhesion junction, MAPK and Wnt signaling. Furthermore, we obtained the differently expressed miRNA-target relationships according to the θ value which is used to calculate the regulation extent of miRNA-target and using the databases of miRanda, Targetscans and Pictar. Among the top 10 miRNA-target relationships, hsa-miR-198 and its potential targeted gene DCX and NNAT were selected for validation, and NNAT was found to be the direct target of miR-198. Finally, the functional roles of miR-155-5p and miR-124-3p whose expressions altered significantly between GSCs and NSCs were addressed. Our results provide new clues for the potential mechanisms involved in the origin and development of glioma. Clinically, the altered miRNAs may serve as potential targets and diagnostic tools for novel therapeutic strategies of glioblastoma. J. Cell. Biochem. 115: 1368-1380, 2014. © 2014 Wiley Periodicals, Inc.
Li G.,Navy General Hospital PLA |
Fan Z.-J.,Navy General Hospital PLA |
Peng X.-J.,Navy General Hospital PLA
Chinese Journal of Ophthalmology | Year: 2013
Objective: To evaluate the efficacy and safety of riboflavin-ultraviolet-A (UV-A) -induced corneal collagen cross-linking (CXL) in the management of progressive keratoconus. Methods: It was a retrospective case series study. Twenty-three eyes of 13 patients with progressive keratoconus were included. Corneal collagen crosslinking was performed under topical anesthesia including corneal deepithelization (8 mm diameter) and instillation of 0.1% riboflavin (in 20% dextran T500 solution) every 3 minutes for a total of 30 minutes. The irradiation is performed for another 30 min using a solid-state UV-A illuminator at 370 nm and an irradiance of 3 mW/cm. Average follow-up was 15. 23 ± 3.39 months (range; 12 to 22 months). Visual acuity, corneal topography, in vivo confocal microscopy, and endothelial cell count were evaluated at baseline and at 1, 3, 6, and 12 months follow-up. Results: Mean uncorrected visual acuity (UCVA) and best spectacle-corrected visual acuity (BSCVA) increased 0.115 ± 0.158 LogMAR (t=3.418, P=0.0026) and 0.114 ± 0.218 LogMAR (t=2.441, P=0.0236) 12 months postoperatively respectively. Interim analysis of treated eyes showed a flattening of the steepest simulated keratometry value (K-max) and astigmatism by an average of (1.893 ± 3.713) diopters (D) (t=2.391, P=0.0262) and (0.117 ± 1.488) D(t=0.370, P=0.715) respectively at 12 months. Central corneal thickness decreased by (27.5 ± 26.8) μm (t=4.812, P=0.000) and (1.54 ± 19.4) μm(t=0.147, P=0.885) at one month and 12 months postoperatively respectively. Intraocular pressure, endothelial cell count, lens and fundus didn't change significantly at 12 months follow-up. Conclusions: CXL stabilised and improved the UCVA and BSCVA as well as the maximum k-readings at 1 year postoperatively in our cohort. It seems to be a safe and promising procedure to stop the progression of keratoconus. Copyright © 2013 by the Chinese Medical Association.